Furthermore, the advantages and disadvantages of participating are mentioned and contact information for advice from an independent physician is given. The researcher contacts the GPs several days after receipt of the letter. When more information is needed, the researcher visits the GP to inform him/her more extensively about the trial. When a GP refuses to participate, the researcher will document the arguments for non-respondent analysis. Rapamycin clinical trial inclusion starts at April 1 2011 and runs to October 1 2012. When the patient and the family caregiver decide to join the study, they sign the informed consent form during a one-hour home visit by the researcher. After informed consent, the Inhibitors,research,lifescience,medical patient and the family caregiver

will first complete the baseline measurement. The baseline measurement consists of several demographic questions and four short questionnaires for the patient. The four questionnaires (ESAS, PNPC-sv, HADS and NCQ) will be completed at home every four weeks during the study Inhibitors,research,lifescience,medical participation. The ESAS will be completed every week, Inhibitors,research,lifescience,medical as symptom burden is our primary outcome. The family caregiver completes a questionnaire on self-perceived pressure from informal care (EDIZ) at baseline and every two weeks. At time points where there is no home visit, the ESAS and EDIZ will be returned in a stamped

envelope. The family caregiver receives a mobile phone text message as a reminder to fill in and post the questionnaires. The flowchart of the inclusion is described in Figure ​Figure11. Figure 1 Flowchart of the inclusion. Outcome measures Primary outcome The symptom burden experienced by the patient, using the Edmonton Symptom Assessment System (ESAS) and the Hospital Anxiety and Depression Scale (HADS). Secondary outcomes Inhibitors,research,lifescience,medical 1. The number of hospital admissions, which will be obtained from the patient’s file. 2. The experienced problems and needs Inhibitors,research,lifescience,medical for palliative care (PNPC-sv; Problems and Needs in Palliative Care). 3. Patient and caregiver satisfaction with the teleconsultation (PSQ; Patient Satisfaction Questionnaire). 4. The experienced continuity of medical care in the last phase of life (Nijmegen

Continuity Questionnaire; NCQ). 5. The experienced burden of the family caregiver Linifanib (ABT-869) (EDIZ; self-perceived pressure from informal care). Other study outcomes 1. We will ask for some demographic information, such as age, marital status, number of children and living situation. 2. After the period of study inclusion (from the GPs patient record): • Number of contacts by telephone with the GP practice • Number of home visits by the GP • Number of contacts with the GPs out of hours service • Number of patients with complex interventions (such as palliative sedation) • Number of and indications for hospital admissions • Date and place of death Measurement instruments The vulnerable condition of the patients was an important point of departure in the selection of the questionnaires.